Financial Performance - Net investment income for the quarter ended June 30, 2025, was $364 million, or $039 per share[9] - Net realized and change in unrealized losses on investments for the quarter were $(180) million, or $(020) per share[9] - Net asset value per share decreased by 12% to $1475 as of the end of the quarter[9] Investment Portfolio - The total investment portfolio amounted to $333 billion, diversified across 249 portfolio companies and 51 industries[10] - Direct origination and other investments represented 92% of the total portfolio[10] - Non-accrual investments accounted for 20% of the total portfolio at fair value[10] - New investment commitments totaled $262 million across 31 companies, averaging $844 million per commitment[9] Portfolio Composition & Characteristics - The direct origination portfolio was primarily composed of first lien loans, representing 99% of the portfolio[10] - The direct origination portfolio was 100% floating rate[10] - Sponsored investments accounted for 90% of the direct origination portfolio[10] Funding and Leverage - Gross fundings for the quarter, excluding revolver fundings, totaled $254 million[9] - Net fundings, including revolvers, totaled $144 million for the quarter[9] - The company's net leverage ratio was 144x as of June 30, 2025[9]

Financial Performance & Guidance - Q3 2025 revenue reached $603 million[12], while adjusted EBITDA was $27 million[12] - The company reaffirmed its FY25 adjusted EBITDA guidance of $0-$20 million[12] - The company expects to be at the bottom end of the revenue guidance range of $2.6 billion[12] primarily due to slower US production ramp - The company delivered a 15.4% adjusted gross profit margin in Q3 2025[35] - The company has approximately $460 million in total cash as of June 30, 2025[12] Backlog & Pipeline - The company has approximately $4.9 billion in backlog as of June 30, 2025[12] - The company's pipeline is approximately $23.5 billion as of June 30, 2025[12] - $2.5 billion of FY'26 revenue is now secured in backlog[12] OBBBA & Tariffs - The Inflation Reduction Act (IRA) extends Section 48E ITC for storage through 2034, providing long-term security[16] - The IRA incentivizes an additional 10% ITC if minimum domestic content thresholds are met[16] - The company is working with domestic suppliers to ensure compliance with the OBBBA by the end of the year[19] - The total tariff on Chinese batteries in calendar year 2025 is projected to be 40.9%, and 58.4% in 2026[21] Market & Strategy - Two Australia contracts totaling approximately $700 million were added to the backlog[11] - Battery storage is now more cost-effective than gas, driving increased data center opportunities[44]

Financial Performance - Total revenue reached $28.6 million, a 13% year-over-year increase driven by improved Average Selling Price (ASP) and end-market diversification[6] - Gross margin was 33.3%, reflecting sustainable improvement in PAC performance[6] - Adjusted EBITDA was $3.7 million, compared to $1.1 million in the prior year period, marking 5 consecutive quarters of positive Adjusted EBITDA[7, 11] - PAC pricing grew by 9% year-over-year in Q2 2025, with an average quarterly growth of approximately 16% in PAC ASP since Q2 2023[6, 16] GAC Commissioning and Expansion - The company completed the commissioning of its transformational GAC facility at Red River, with ramp-up to nameplate capacity underway[6, 24] - The company is targeting a Final Investment Decision (FID) for a 2nd GAC line prior to year-end 2025[8, 27] - The Red River plant is expected to add production of GAC and expand the plant to deliver an incremental 25 million pounds of GAC product[32] Market and Regulatory Landscape - EPA regulations could boost municipal water market demand by 3 to 5 times from approximately 170 million pounds per year[37] - The company is benefiting from U S tariffs due to its fully integrated domestic supply chain[38] Strategic Initiatives - The company is developing new markets, including the Arq-Enabled Great Lakes Restoration Project, which is the largest PAC sediment remediation in U S history[41, 42] - The company is exploring growth beyond activated carbon, with multiple initiatives focused on developing additional product opportunities and revenue streams from Corbin feedstock[43]

Financial Performance - Q2 2025 consolidated revenue was $95 million, reflecting an 8% QoQ rebound excluding Geomagic[29] - Medical Technologies revenue grew 13% YoY and 16% QoQ, representing over $80 million of FY'24 revenues[19] - The company achieved significant OpEx reductions of $17 million YoY and $15 million QoQ[35] - Net income for Q2 2025 was $1044 million, with GAAP EPS at $057[39] - The company expects to exit Q4'25 with operating expenses in the low $40 million range[13] Strategic Initiatives - The company completed the sale of the Geomagic business for nearly $120 million in cash on April 1, 2025[10, 44] - A debt transaction in June permanently retired $88 million in debt and refinanced $92 million through 2030, along with repurchasing 8 million common shares[10, 44] - Cost reduction and profitability improvement initiatives target over $85 million of annualized savings planned through 1H'26[12] Balance Sheet - The company ended the quarter with approximately $134 million in cash, cash equivalents, and restricted cash[44] - As of August 2025, the company's global cash, cash equivalents, and restricted cash amounted to approximately $130 million[44]

Financial Performance - Q4 FY25 - Revenue remained flat at $60.159 billion[9] - Gross margin increased by 17% to $2.202 billion[9] - Operating earnings increased by 7% to $428 million on a GAAP basis and 19% to $719 million on a non-GAAP basis[9] - Net earnings increased by 2% to $239 million on a GAAP basis and 11% to $501 million on a non-GAAP basis[9] - Diluted EPS increased by 4% to $1.00 on a GAAP basis and 13% to $2.08 on a non-GAAP basis[9] Segment Performance - Q4 FY25 - Pharmaceutical and Specialty Solutions revenue decreased by 0% to $55.372 billion, while segment profit increased by 11% to $535 million[11] - Global Medical Products and Distribution revenue increased by 3% to $3.199 billion, and segment profit increased significantly by 49% to $70 million[15] - Other (NPHS, at-Home Solutions, and OptiFreight) revenue increased by 37% to $1.609 billion, with segment profit increasing by 44% to $160 million[20] Financial Performance - FY25 - Revenue decreased by 2% to $222.578 billion[28] - Gross margin increased by 10% to $8.168 billion[28] - Operating earnings increased significantly by 83% to $2.275 billion on a GAAP basis and 15% to $2.786 billion on a non-GAAP basis[28] - Net earnings increased significantly by 83% to $1.561 billion on a GAAP basis and 7% to $1.995 billion on a non-GAAP basis[28] - Diluted EPS increased significantly by 87% to $6.45 on a GAAP basis and 9% to $8.24 on a non-GAAP basis[28] Segment Performance - FY25 - Pharmaceutical and Specialty Solutions revenue decreased by 3% to $204.644 billion, but segment profit increased by 12% to $2.258 billion[30] - Global Medical Products and Distribution revenue increased by 2% to $12.636 billion, with segment profit increasing significantly by 47% to $135 million[35] - Other (NPHS, at-Home Solutions, and OptiFreight) revenue increased by 19% to $5.382 billion, and segment profit increased by 22% to $516 million[40] FY26 Outlook - Non-GAAP EPS is expected to be in the range of $9.30 - $9.50, revised from the previous outlook of $9.10 to $9.30[48] - Interest and Other expenses are projected to be approximately $275 million[48] - Non-GAAP adjusted free cash flow is expected to be between $2.75 billion and $3.25 billion[48]

Market Context - The market demands 24/7 scalable power with pathways to reduce emissions, and natural gas is well-suited to meet this need[6] - The 2025 PJM capacity auction clearing prices increased over 11x, from $29/MW-day in 2023 to $329/MW-day[7] - There's a pragmatic shift towards responsible natural gas use while focusing on decarbonization, driven by federal emphasis on domestic energy and affordability[10] - Newly enacted parity for 45Q credit for EOR is increasing value from $60 to $85[10] Integrated Product - Integrating Net Power with gas turbines offers industrial, economic, and environmental advantages, accelerating market adoption[13] - Integrating simple cycle gas turbines with Net Power doubles power output with half the emissions of a standard 200 MWe gas plant[19] - The integrated product design offers flexibility, creating multiple pathways to meet long-term power and environmental goals[20, 21] Project Permian - Value engineering, favorable tax policy changes, and the integrated product yield a ~33% reduction in targeted LCOE for Project Permian[23] - Project Permian's LCOE is targeted to be under $100/MWh, a reduction from over $150/MWh in May 2025[24] Operations Update - Baker Hughes equipment validation at La Porte is underway, with Phase 1 testing expected to be completed in 2025[28, 29]

Q2 2025 Key Performance Highlights - Funded Accounts reached 363 million, a 14% year-over-year increase[12] - Assets Under Administration (AUA) totaled $175 billion, up 54% year-over-year[12] - Net Contribution amounted to $210 million, reflecting a 26% year-over-year growth[12] - Adjusted EBITDA was $72 million, a 31% increase compared to the previous year[12] Business Strategy and Product Updates - The company is focused on four strategic pillars: Trading, Investing, Wealth Management, and Neo-Banking, to drive global expansion and product localization[15, 16, 17, 18, 19] - New product launches include 24/5 trading for U S equities and futures, new Smart Portfolios with Franklin Templeton, French savings products, and the eToro Card now available in multiple E U markets[22, 23, 26, 27] - The company is expanding its crypto offering in the U S, providing access to over 100 tokens[28] - The company launched Tori, an AI analyst providing personalized investment insights[29] Financial Performance Details - Net Trading Contribution from Equities, Commodities, and Currencies was $114042 thousand for the three months ended June 30, 2025[123] - Revenue from Cryptoassets was $1914792 thousand for the three months ended June 30, 2025[123] - Net income for Q2 2025 was $30185 thousand, which includes $15 million of IPO and other related costs[110, 130]

Liquidia Corporation 2Q2025 Financial Results & Corporate Update August 12, 2025 ©2025 LIQUIDIA CORPORATION ALL RIGHTS RESERVED Forward-looking statements ©2025 LIQUIDIA CORPORATION ALL RIGHTS RESERVED 3 Rapid adoption over last 11 weeks! As of August 8, 2025 This presentation includes, and our response to questions may include, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). All statements contained in this presentation other than statements ...

Commercial Performance - 2Q 2025 net product revenues reached $18.1 million, a 6.2% increase compared to $17.0 million in the same quarter of 2024 [16, 58] - Total 1H 2025 net product revenue was $35.5 million, up from $34.9 million during the 1H of 2024 [16] Pipeline Progress - LOTIS-7 data showed a 93.3% ORR (Overall Response Rate) and an 86.7% CR (Complete Response) rate across 30 efficacy evaluable patients when ZYNLONTA was combined with glofitamab [16, 53] - Updated MZL IIT data presented at ICML demonstrate an 85% ORR and a 69% CR rate [16] - LOTIS-5 is on track to reach pre-specified PFS (Progression-Free Survival) events by the end of 2025 [16] Corporate Update - The company secured $100 million in private placement, extending the expected cash runway into 2028 [16] - A strategic prioritization was implemented, resulting in a 30% reduction in force and one-time charges of $13.1 million, including $6.7 million in employee severance and $6.4 million in non-cash impairment of assets related to the UK facility closure [16] - The company's cash balance was $264.6 million as of June 30, 2025 [16, 58] LOTIS-7 Trial Safety - In the LOTIS-7 Phase 1b trial, 56.1% of patients experienced Grade 3/4 TEAEs (Treatment-Emergent Adverse Events) [47] - Cytokine Release Syndrome (CRS) of any grade was observed in 39% of patients [49] - ICANS (Immune effector Cell-Associated Neurotoxicity Syndrome) of any grade was observed in 7.3% of patients [49] ZYNLONTA Market Potential - ZYNLONTA has a U S peak revenue potential of $600 million to $1 billion in DLBCL (Diffuse Large B-Cell Lymphoma) and indolent lymphomas [21, 22]

Financial Performance - Net sales decreased to $39245 thousand in Q2 2025 from $54793 thousand in Q2 2024 [23] - Adjusted Gross Profit decreased to $7531 thousand in Q2 2025 from $13349 thousand in Q2 2024 [23] - Adjusted Gross Profit Margin decreased to 192% of net sales in Q2 2025 from 244% in Q2 2024 [23] - Adjusted SG&A increased to 250% of net sales in Q2 2025 from 212% in Q2 2024, while the actual expense decreased to $9803 thousand from $11624 thousand [23] - Adjusted EBITDA decreased to $(2272) thousand in Q2 2025 from $1725 thousand in Q2 2024 [23] Strategic Initiatives and Restructuring - A new restructuring plan was initiated to optimize the product portfolio, distribution center, and manufacturing footprint [13, 16] - The company anticipates over $3 million in estimated annual cost savings from the restructuring plan, along with improvements in working capital [16] - The company is focused on higher-margin proprietary brands by eliminating underperforming brands [16] - The company expects improved Adjusted Gross Profit Margin and reduced year-over-year Adjusted SG&A expense for full year 2025 [20] Liquidity and Debt - Cash balance as of June 30, 2025, was $110 million [30] - Liquidity, defined as cash plus available borrowing capacity, was $200 million as of June 30, 2025 [30] - Free Cash Flow for the three months ended June 30, 2025, was $14 million [30] - Total debt outstanding as of June 30, 2025, was $1226 million, with net debt at $1116 million [30]